Fully Human Antibody / TCR Platforms

Bispecific Antibody

Bispecific antibodies (BsAbs) offer unique advantages by targeting two antigens simultaneously, enabling enhanced specificity, overcoming resistance, and addressing disease heterogeneity. They optimize pharmacokinetics, reduce off-target effects, and support diverse mechanisms such as pathway blockade and immune cell redirection, unlocking broad therapeutic potential.
  • The ability to simultaneously target multiple tumor-driven proteins, potentially overcoming drug resistance.
  • Recognition of cells co-expressing both targets to increase tumor specificity and reduce off-target toxicity.
  • The combination of two selected targets increases internalization and thus tumor killing.
  • 10+
    Fully-human BsAbs
  • 10+
    TCR mimic Assets

on this page

  • Advantages of Biocytogen's BsAb Platform
  • Discovery of Novel Bispecific Antibodies
  • Off-the-shelf BsAbs Available for Partnership
  • FAQs

Webinars

View All

    Posters

    View All

      Advantages of Biocytogen's BsAb Platform

      • Versatile Design: Enables the assembly of diverse components like scFv, peptides, VHHs, and cytokines with flexible formats supported by technologies like Knobs-into-Holes.
      • Common Light Chain Advantage: Produces fully human common light chain antibodies for efficient and precise bispecific assembly with minimal mispairing.
      • High-Quality Antibodies: Combines RenLite KO mice and Beacon technology to generate antibodies with exceptional diversity and affinity.
      • Scalable Validation: Employs a robust in vivo system to identify effective and safe target combinations.
      • Bifunctional Molecules: Develops antibody-cytokine molecules with superior synergy, enhancing the druggability of cytokine-based therapies.

      Biocytogen's RenLite-based BsAb Platform

      BsAb developed from RenLite mice

      BsAb developed from RenLite mice

      Off-the-shelf BsAbs Available for Partnership

      Format Therapeutic Area Product Number Target(s) Immunization
      • Development
      • Hits
        selection
        Leads
        selection
        Candidate
        selection
      Preclinical IND Phase I Status
      BsAb Oncology YH008 PD-1 x CD40
      Partnered ex-China rights available
      BsAb Oncology YH006 OX40 x CTLA4
      BsAb Oncology BCG021 4-1BB x CD40
      BsAb Inflammation and Autoimmunity BCG028 OX40 x OX40
      BsAb Oncology - CD40 x CTLA4
      BsAb Oncology BCG051 GDF15 x VEGFA
      BsAb Inflammation and Autoimmunity - IL4RA x KIT
      BsAb Inflammation and Autoimmunity - IL13 x TSLP
      BsAb Inflammation and Autoimmunity - IL17A x IL17F x IL4RA
      BsAb Oncology - B7-H3 x FN1
      TCE Oncology - CDH17 x CD3 x CD28
      TCE Oncology - STEAP1 x CD3e
      TCE Oncology BCG024 DLL3 x CD3 x 4-1BB
      Tri-Ab Oncology BCG038 EGFR x VEGFA x CD98
      Tri-Ab Oncology - PD-L1 x CD98 x VEGFA
      Tri-Ab Inflammation and Autoimmunity - C2 x FCGRT x ALB
      Tri-Ab Oncology - PD-L1 x IL11 x VEGFA
      Tri-Ab Oncology - PD-L1 x VEGFA x IL27R

      Frequently Asked Questions (FAQs) About Bispecific Antibody Platform

      1. What is a bispecific antibody, and what unique mechanisms of action does it offer beyond conventional monoclonal antibodies?

      A bispecific antibody (BsAb) recognizes two different antigens or epitopes within a single molecule. This dual specificity enables novel therapeutic mechanisms beyond conventional monospecific antibodies, including: dual pathway blockade, receptor co-localization or clustering, and immune-cell redirection such as T-cell engagers (TCEs).

      2. What antibody formats and modalities does Biocytogen’s bispecific antibody platform support?

      Biocytogen’s platform supports fully human bispecific, biparatopic, and multispecific antibody formats. Flexible architectures can incorporate common light chain antibodies, VHHs, scFvs and cytokines to meet diverse therapeutic design needs. In addition to unconjugated BsAbs and BpAbs, Biocytogen has also established a platform that enables selected bispecific antibody backbones to be further developed into bispecific antibody-drug conjugates (BsADCs).

      3. What are the advantages of developing biparatopic antibodies (BpAbs)?

      BpAbs bind two distinct, non-overlapping epitopes on the same antigen to overcome the limitations of conventional monoclonal antibodies. Key advantages include:
      • Enhanced target engagement: Achieves greater receptor occupancy and more complete ligand blockade compared with single-epitope antibodies.
      • Differentiated functional activity: Modulation of receptor clustering, internalization, or signaling to enhance therapeutic activity.
      For example, Biocytogen’s BCG028, a biparatopic OX40 antagonist, leverages dual-epitope binding to reduce OX40-mediated T-cell costimulatory signaling, delivering superior in vivo efficacy in preclinical models.

      4. How does Biocytogen address chain mispairing in bispecific antibody generation?

      Biocytogen combines complementary engineering strategies to simplify fully human bispecific and multispecific antibody assembly:
      • RenLite®-derived common light-chain antibodies: Use a shared light chain to avoid mispairing between different heavy and light chains.
      • Fully human VHH antibody integration: Provide compact, modular single-domain building blocks that require no light chain, reducing pairing complexity.
      • Knobs-into-Holes (KIH) engineering: Applied to promote correct pairing between two different heavy chains.
      Together, these approaches address distinct chain-pairing challenges, simplifying antibody assembly and supporting favorable developability.

      5. How does Biocytogen discover and evaluate fully human bispecific antibody candidates?

      Biocytogen uses RenLite® or RenLite® target-gene KO mice to generate fully human common light-chain antibodies. Beacon-based single-cell screening with AI-powered selection supports accelerated candidate identification. Candidates are then evaluated in in vivo studies, including target-humanized mouse models, to assess efficacy and safety with high translational potential.

      6. What off-the-shelf antibody libraries does Biocytogen offer for bispecific antibody development?

      Biocytogen offers more than 200 TAA-specific fully human antibody backbones for plug-and-play bispecific antibody (BsAb) development. Through RenSuper™ Workstation, partners can also access broader antibody libraries spanning over 1,000 targets to identify building blocks for customized and scalable BsAb development.